Scholar Rock (NASDAQ:SRRK) Trading Down 4.3% - Should You Sell?

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) traded down 4.3% during mid-day trading on Monday . The company traded as low as $43.04 and last traded at $43.21. 149,001 shares were traded during trading, a decline of 73% from the average session volume of 552,993 shares. The stock had previously closed at $45.17.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SRRK shares. HC Wainwright upped their target price on shares of Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Piper Sandler increased their price objective on Scholar Rock from $28.00 to $42.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 15th. Truist Financial lifted their target price on Scholar Rock from $36.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, November 25th. JPMorgan Chase & Co. increased their price target on Scholar Rock from $18.00 to $31.00 and gave the company an "overweight" rating in a research report on Monday, October 14th. Finally, Wedbush lifted their price objective on shares of Scholar Rock from $40.00 to $47.00 and gave the stock an "outperform" rating in a report on Monday, November 25th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Scholar Rock has an average rating of "Buy" and a consensus price target of $40.43.

Scholar Rock Price Performance

The stock has a market cap of $4.01 billion, a P/E ratio of -18.24 and a beta of 0.52. The business has a 50 day simple moving average of $36.95 and a 200-day simple moving average of $20.93. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the business's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $38.49, for a total value of $15,759,076.17. Following the sale, the insider now directly owns 10,850,005 shares in the company, valued at $417,616,692.45. The trade was a 3.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 19.20% of the company's stock.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Scholar Rock by 3.1% in the third quarter. FMR LLC now owns 10,196,046 shares of the company's stock worth $81,670,000 after purchasing an additional 308,813 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Scholar Rock by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock worth $12,361,000 after buying an additional 120,489 shares during the period. Millennium Management LLC grew its stake in Scholar Rock by 159.2% in the 2nd quarter. Millennium Management LLC now owns 925,584 shares of the company's stock valued at $7,710,000 after buying an additional 568,512 shares in the last quarter. Hood River Capital Management LLC raised its holdings in Scholar Rock by 5.1% during the 2nd quarter. Hood River Capital Management LLC now owns 832,792 shares of the company's stock valued at $6,937,000 after acquiring an additional 40,745 shares during the period. Finally, abrdn plc lifted its position in shares of Scholar Rock by 28.2% during the third quarter. abrdn plc now owns 748,489 shares of the company's stock worth $5,995,000 after acquiring an additional 164,715 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.